Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2005
10/04/2005US6951937 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
10/04/2005US6951923 For regenerating tissues; antiaging agents; medical diagnosis; monitoring chemotherapy
10/04/2005US6951918 Treatment of diseases characterized by excessive deposits of fibrillar interstitial collagens that are resistant to proteolyic degradation thus leading to symptoms of fibrosis
10/04/2005US6951916 Melanocortin receptor ligands
10/04/2005US6951890 Preventing and/or treating cardiovascular disease and/or associated heart failure
10/04/2005US6951889 7-acetamidinyl derivatives
10/04/2005US6951885 Pharmaceutical composition
10/04/2005US6951883 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof
10/04/2005US6951879 Heteroaromate OSC inhibitors
10/04/2005US6951874 Compounds
10/04/2005US6951871 Indole derivatives useful as histamine H3 antagonists
10/04/2005US6951865 Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same
10/04/2005US6951862 Calcium channel blockers comprising two benzhydril moieties
10/04/2005US6951856 Substituted pyrimidine-sulfonamide derivatives are used as endothelin receptor antagonists
10/04/2005US6951855 vascular damaging agents
10/04/2005US6951850 Dipeptide derivatives
10/04/2005CA2262862C Angiogenic inhibitory compounds
10/04/2005CA2245539C Condensed 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
09/2005
09/30/2005CA2499791A1 Angptl4/fiaf as marker for ppardelta modulation
09/29/2005WO2005090974A1 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
09/29/2005WO2005090574A1 Vascular endothelial growth inhibiting gene
09/29/2005WO2005090564A1 Gene promoting vascular endothelial cell growth
09/29/2005WO2005090340A1 Piperidine-1-carboxamide derivative
09/29/2005WO2005090332A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005WO2005090328A1 Heterocyclic compound and use thereof
09/29/2005WO2005090285A1 Novel crystal of triterpene derivative
09/29/2005WO2005089822A1 Medicine/gene leaching type stent
09/29/2005WO2005089714A1 Emulsion stabilizer
09/29/2005WO2004105752A8 Substituted pyrrole derivatives as hmg-coa reductase inhibitors
09/29/2005WO2003076469A9 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
09/29/2005WO2003074057A8 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
09/29/2005US20050216958 Fucosyltransferase knock-out host cell for use as bioreactors in production of preferentially modified glycoproteins
09/29/2005US20050215632 Preventive or remedy for hypertension
09/29/2005US20050215630 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
09/29/2005US20050215613 with indazole or thienopyrazole compounds such as 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl-indazole
09/29/2005US20050215607 Drug composition for prevention or inhibition of advance of diabetic complication
09/29/2005US20050215596 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals
09/29/2005US20050215594 Diabetes, obesity, urogenital disorders, cardiovascular disorders, atherosclerosis; 4-[(2R)-2-(([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid for example
09/29/2005US20050215593 Kaposi's sarcoma; Crohn's disease
09/29/2005US20050215574 4-anilino quinazoline derivatives as antiproliferative agents
09/29/2005US20050215559 2-substituted, especially 2-amino-substituted, e.g., [N-(1-ethyl)propyl]-5-(2,4-dimethoxyphenyl)-3,6-dimethylpyrazine-2-amine; bind with high affinity and high selectivity to CRF1 receptors and are used to treat central nervous system disorders
09/29/2005US20050215553 For therapy and prophylaxis of cardiovascular, central nervous system, inflammatory, and bone diseases as well as infectious diseases and certain cancers
09/29/2005US20050215550 Pyrazole-derived kinase inhibitors and uses thereof
09/29/2005US20050215549 TACE inhibitors
09/29/2005US20050215547 Optically active pyridine derivative and a medicament containing the same
09/29/2005US20050215537 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
09/29/2005US20050215534 Antiinflammatory agents; asthma; chronic obstructive pulmonary disease; dermatitis; antiallergens; antitumor agents; Aida; antiischemic agents; arrhythmia
09/29/2005US20050215533 Administering to mammal an effective amount of sulfaphenazole wherein the administered sulfaphenazole substantially reduces the amount of infracted tissue
09/29/2005US20050215530 Combination therapy for the treatment of cancer
09/29/2005US20050215528 Gnrh agonist combination drugs
09/29/2005US20050215520 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
09/29/2005US20050215518 Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
09/29/2005US20050215502 Regulation of endogenous gene expression in cells using zinc finger proteins
09/29/2005US20050215497 Treating prostate cancer by administering double stranded oligonucleotide having two complementary oligonucleotide sequences forming a hybrid; each sequence has at one 3' or 5' end 1-5 unpaired nucleotides forming single-strand ends extending beyond the hybrid
09/29/2005US20050215496 Preparation and diabetic use of Gibberellins
09/29/2005US20050215477 Treating agonist disorderssuch asd diabetes, obesity, heart dysfunctions, AIDS-related wasting, and kidney, neurological, whole body growth disorders by administering a crystal of an insulin-like growth factor-1 that diffracts x-ray radiation to produce a three-dimensional diffraction pattern
09/29/2005US20050215469 Reducing food intake; obesity; dietetics
09/29/2005US20050215467 Multimeric Apo A-I agonist compounds
09/29/2005US20050214903 O-superfamily conotoxin peptides
09/29/2005US20050214835 Diagnosis and treatment of myocardial failure
09/29/2005US20050214762 Receptor binding domains of leptin; proteolysis; fusion proteins
09/29/2005US20050214761 For introducing DNA into organisms which produce large amounts of oils and, in particular, oils with a high content of unsaturated fatty acids
09/29/2005US20050214387 Low-dose potassium supplementation for the prevention and treatment of hypertension
09/29/2005US20050214385 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia
09/29/2005US20050214384 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
09/29/2005US20050214352 Patch and process for producing the same
09/29/2005US20050214346 For reducing serum cholesterol by increasing high density lipoprotein concentration; hypercholesterolemia
09/29/2005US20050214299 Method of inhibiting stenosis and restenosis
09/29/2005US20050214291 Treatment method
09/29/2005US20050214281 G-protein coupled receptor
09/29/2005US20050214253 Interferon-beta fusion proteins and uses
09/29/2005DE10393402T5 Mittel und Toilettenartikel- oder pharmazeutische Zusammensetzung zum Beschleunigen der Aufnahme von basischen Aminosäuren in Zellen Means and Toilettenartikel- or pharmaceutical composition to accelerate the uptake of basic amino acids in cells
09/29/2005DE10393290T5 Clopidogrel Clopidogrel
09/29/2005CA2562388A1 Emulsion-stabilized preparation
09/29/2005CA2560767A1 Novel crystal of triterpene derivative
09/29/2005CA2560286A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005CA2560199A1 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
09/29/2005CA2560195A1 Organic compounds
09/29/2005CA2559838A1 Y2 selective receptor agonists for therapeutic interventions
09/29/2005CA2559545A1 Tetra-cyclic carboline derivatives for inhibiting angiogenesis
09/29/2005CA2559211A1 Detection, isolation and uses of renalase (monoamine oxidase c)
09/29/2005CA2558169A1 Method of treatment of myocardial infarction
09/29/2005CA2558020A1 Use of renin inhibitors in therapy
09/29/2005CA2558015A1 Method for treating aortic stenosis with non-antibacterial tetracycline formulations
09/28/2005EP1580192A2 16-Hydroxyestratrienes as selective estrogens
09/28/2005EP1580188A1 Aryl ureas as kinase inhibitors
09/28/2005EP1579877A1 Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
09/28/2005EP1579871A1 Vascular endothelial cell growth factor antagonists and uses thereof
09/28/2005EP1579868A2 Use of IL-11 for treating various diseases
09/28/2005EP1579867A1 Medicinal composition for treating ischemic cardiac failure
09/28/2005EP1579010A2 Susceptibility gene for myocardial infarction; methods of treatment
09/28/2005EP1578914A2 Human ion channels
09/28/2005EP1578912A2 Il-13 mutein proteins, antibodies, compositions, methods and uses
09/28/2005EP1578902A2 Neurotransmission-associated proteins
09/28/2005EP1578899A2 Secreted proteins
09/28/2005EP1578798A1 Ghrelin receptor inverse agonist for regulation of feeding behaviours
09/28/2005EP1578787A1 Novel chi-conotoxin peptides (-ii)
09/28/2005EP1578737A1 Substituted heterocyclic compounds
09/28/2005EP1578735A1 Cyclopentyl glutaramides and their use as neutral endopeptidase inhibitors
09/28/2005EP1578725A1 Microsomal triglyceride transfer protein inhibitors
1 ... 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 ... 1595